Marlborough: Hologic Inc announced it has entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to US$79 per share, representing an enterprise value of up to US$18.3 billion. (US$1=RM4.22)

According to BERNAMA News Agency, shareholders will receive US$76 per share in cash, plus a non-tradable contingent value right (CVR) worth up to US$3 per share, tied to performance milestones in Hologic’s Breast Health business through fiscal 2027. The aggregate purchase price represents a premium of approximately 46 percent to Hologic’s closing price on May 23, 2025, the day before media reports of a potential transaction surfaced.

In a statement, Hologic said the transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC. Hologic Chairman, President and Chief Executive Officer, Stephen P. MacMillan, stated that the deal will accelerate innovation and expand access to Hologic’s women’s health technologies. He noted that this transaction delivers immediate value to Hologic stockholders, acknowledging the dedication of employees in reaching this milestone.

The company, which will remain headquartered in Marlborough, Massachusetts, will go private and delist from Nasdaq upon closing, expected in the first half of 2026. Blackstone and TPG have secured financing from top-tier banks, including Citi, Bank of America, Barclays, Royal Bank of Canada, and SMBC. The deal includes a 45-day ‘go-shop’ period, allowing Hologic to entertain superior bids.

With no earnings calls planned during the transaction period, the market’s next update from Hologic will be its fourth-quarter results on Nov 3 and its 10-K filing in late November. This acquisition underscores private equity’s growing interest in scaled, innovation-driven healthcare platforms and positions Hologic for its next phase of growth under private ownership.